Updated Jul 16, 2026
Eckert Celia is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $74K.
Celia Eckert is a legal professional with significant experience in the biotechnology sector. She serves as the Senior Vice President and General Counsel at Xencor Inc, a biopharmaceutical company focused on developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases.
| Role | SVP, GENERAL COUNSEL |
|---|---|
| Notability | 60/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-09 | XNCR | Xencor Inc | S — Open-market sale | 1.8K | $11.02 | $19K |
| 2026-03-09 | XNCR | Xencor Inc | S — Open-market sale | 3.2K | $11.25 | $36K |
| 2026-03-05 | XNCR | Xencor Inc | S — Open-market sale | 1.5K | $11.90 | $18K |
| 2026-03-05 | XNCR | Xencor Inc | A — Grant or award | 18.7K | $0.00 |
Celia Eckert is a legal professional with significant experience in the biotechnology sector. She serves as the Senior Vice President and General Counsel at Xencor Inc, a biopharmaceutical company focused on developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases.…
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($74K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Eckert Celia profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.